Summit Therapeutics Inc. Common Stock (SMMT) exhibits 41.0% gross margins and -35.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 6.8% implied options volatility.
Sustained 41.0% gross profitability converts into -36.3% operating margin and -35.0% ROIC, outpacing sector cost of capital.
ROIC: -35.0% // GM: 41.0%YoY revenue trajectory of +11.0% paired with -2.50% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +11.0% // FCF YLD: -2.50%Altman Z-Score of 26.00 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 5/9Trading at 24.0x trailing P/E (34.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±6.8% implied move with a 0.63 put/call ratio around $16.00 max pain.
IMPL MOVE: ±6.8% // P/C: 0.63Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -29.8% net margins.
NET MARGIN: -29.8% // D/E: 0.06x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SMMT & activate live FRED threshold breach alerts.